Skip to main content

Table 2 Baseline characteristics of the entire patient cohort

From: Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

  No. (%) P
the entire cohort (n = 4262) MRM ± RT (n = 3858) BCS + RT (n = 404)
Year     < .001
 1999–2008 1976 (46.4) 1871 (48.5) 105 (26.0)  
 2009–2014 2286 (53.6) 1987 (51.5) 299 (74.0)  
Age (years)     < .001
 ≤ 40 802 (18.8) 678 (17.6) 124 (30.7)  
 > 40 3460 (81.2) 3180 (82.4) 280 (69.3)  
Tumor location     .755
 Inner quadrant 909 (21.3) 819 (21.2) 90 (22.3)  
 Other quadrants 3292 (77.2) 2985 (77.4) 307 (76.0)  
 Unknown 61 (1.4) 54 (1.4) 7 (1·.7)  
T stage     < .001
 T1 2009 (47.1) 1725 (44.7) 284 (70.3)  
 T2 2253 (52.9) 2133 (55.3) 120 (29.7)  
SLNB     < .001
 No 4099 (96.2) 3782 (98.0) 317 (78.5)  
 Yes 163 (3.8) 76 (2.0) 87 (21.5)  
No. of ALND     .834
 ≤ 19 2721 (63.8) 2465 (63.9) 256 (63.4)  
 > 19 1541 (36.2) 1393 (36.1) 148 (36.6)  
No. of positive nodes     .016
 1 2198 (51.6) 1963 (50.9) 235 (58.2)  
 2 1264 (29.7) 1156 (30.0) 108 (26.7)  
 3 800 (18.8) 739 (19.2) 61 (15.1)  
Lymphovascular invasion     < .001
 No 3457 (81.1) 3109 (80.6) 348 (86.1)  
 Yes 522 (12.2) 470 (12.2) 52 (12.9)  
 unknown 283 (6.6) 279 (7.2) 4 (1.0)  
Histological grade     < .001
 I 133 (3.1) 104 (2.7) 29 (7.2)  
 II 2290 (53.7) 2035 (52.7) 255 (63.1)  
 III 1030 (24.2) 937 (24.3) 93 (23.0)  
 unknown 809 (19.0) 782 (20.3) 27 (6.7)  
Chemotherapy     < .001
 No 239 (5.6) 236 (6.1) 3 (0.7)  
 Yes 3995 (93.7) 3594 (93.2) 401 (99.3)  
 unknown 28 (0.7) 28 (0.7) 0 (0)  
Chemotherapeutic drug     < .001
 Taxane-based 2684 (63.0) 2344 (60.8) 340 (84.2)  
 Others 1105 (25.9) 1057 (27.4) 48 (11.9)  
 Unknown 473 (11.1) 457 (11.8) 16 (4.0)  
Hormone receptor & Hormonal therapy     < .001
 negative & no 913 (21.4) 862 (22.3) 51 (12.6)  
 positive & yes 2862 (67.2) 2537 (65.8) 325 (80.4)  
 positive & no 312 (7.3) 295 (7.6) 17 (4.2)  
 Unknown 175 (4.1) 164 (4.3) 11 (2.7)  
HER2 & Target therapy     < .001
 negative & no 2846 (66.8) 2545 (66.0) 301 (74.5)  
 positive & yes 233 (5.5) 198 (5.1) 35 (8.7)  
 positive & no 619 (14.5) 582 (15.1) 37 (9.2)  
 unknown 564 (13.2) 533 (13.8) 31 (7.7)  
  1. Abbreviations: MRM Modified radical mastectomy, BCS Breast-conserving surgery, RT Radiotherapy, SLNB Sentinel lymph node biopsy, ALND Axillary lymph node dissection, HER2 Human epidermal growth factor receptor 2
\